Latest Galena Biopharma Stories
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
RnRMarketResearch.com adds HER-2 Positive Breast Cancer Market in the US 2015-2019 and Global HER-2 Positive Breast Cancer Market 2015-2019 industry research reports in its store. DALLAS, March
LONDON, March 17, 2015 /PRNewswire/ -- Executive Summary--The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy,
The use of combination targeted therapies will improve progression-free disease as well as survival rates, finds Frost & Sullivan LONDON, March 17, 2015 /PRNewswire/ -- Despite the availability
WORCESTER, Mass. and TORONTO, Feb.
Analysis of Phase I Trial indicates Safety and positive immune response data in 21 of 21 patients administered Folate Receptor Alpha Vaccine for breast and ovarian cancers SEATTLE,
Lead Immunotherapy Product Candidate GEN-1 to Enter Dose Escalating Clinical Study in the Second Half of 2015 LAWRENCEVILLE, N.J., Jan.
- A person in a secondary role, specifically the second most important character (after the protagonist).